Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 2Withdrawn 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 7Dermatologic 3Breast 3Lymphoid 2Genitourinary 2Tumor-Agnostic 1

Conditions

Breast Neoplasms 3Melanoma 1Lymphoma, T-Cell 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Trastuzumab 242Paclitaxel 223Fulvestrant 196Capecitabine 182Docetaxel 164Letrozole 142pembrolizumab 115Carboplatin 100exemestane 98Gemcitabine 98Cyclophosphamide 92palbociclib 86Anastrozole 83pertuzumab 78Lapatinib 73Bevacizumab 71ribociclib 68130-nm albumin-bound paclitaxel 66abemaciclib 59eribulin 58Doxorubicin 55Vinorelbine 51Injections 47Ado-Trastuzumab Emtansine 47Tamoxifen 45Everolimus 44Albumin-Bound Paclitaxel 44atezolizumab 35trastuzumab deruxtecan 34Nivolumab 34

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × ProMune × Breast × Clear all
NCT00471159 2015-05-04

A Study Of Docetaxel Or Docetaxel Plus PF-3512676 To Treat Patients With Advanced Breast Cancer.

Pfizer

Phase 2 Withdrawn
Breast

Breast Neoplasms

NCT00043368 2009-03-12

PF-3512676 (CPG 7909) Injection For Patients Who Completed An Oncology Study Using PF-3512676 (CPG 7909)

Pfizer

Phase 2 Completed
31 enrolled
BreastDermatologicGenitourinaryLymphoidThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Lymphoma, T-Cell

NCT00043394 2009-03-12

CPG 7909 Plus HerceptinĀ® In Patients With Metastatic Breast Cancer

Pfizer

Phase 2 Completed
16 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚔